Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
358 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07085169 | Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC | recruiting | Phase 2 | 50 | Ruijin HospitalOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT03636893 | Dragon III: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer | completed | Phase 2 | 74 | Ruijin HospitalOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT06602674 |
| PET/CT-Based Image Analysis and Machine Learning of Hypermetabolic Pulmonary Lesions |
| completed |
| — |
| 647 |
| Ruijin HospitalOTHER |
| 1 |
| Jul 23, 2025 |
| clinicaltrials |
| NCT07081607 | Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma. | not yet recruiting | Phase 2 | 30 | Ruijin HospitalOTHER | 0 | Jul 23, 2025 | clinicaltrials |
| NCT07072169 | A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) | recruiting | Phase 1 | 56 | Ruijin HospitalOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT07067385 | Personalized mRNA Cancer Vaccine for Gastrointestinal Solid Tumor Treatment(PCV-GSTT) | recruiting | Phase 1 | 40 | Ruijin HospitalOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT06966440 | Adjuvant Pancreatic Therapy Guided by MRD(ADAPT-MRD) | recruiting | N/A | 856 | Ruijin HospitalOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT07028086 | VAM in Secondary AML, AML With Extramedullary Involvement, and Myeloid Sarcoma | recruiting | Phase 2 | 48 | Ruijin HospitalOTHER | 1 | Jul 9, 2025 | clinicaltrials |
| NCT07035002 | Study on the Safety and Tolerability of PD-1 Knockout Tumor-infiltrating T Cells (TILs) in the Treatment of Advanced Colorectal Cancer | recruiting | Phase 1 | 29 | Ruijin HospitalOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT07026149 | Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer | recruiting | Phase 2 | 30 | Ruijin HospitalOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT07015580 | The Characteristics of Oral Microbiota in Chronic Pancreatitis and Autoimmune Pancreatitis | recruiting | — | 360 | Ruijin HospitalOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT07004634 | Comparison of Drainage Methods in Minimally Invasive Esophagectomy (DEMURE） | recruiting | N/A | 75 | Ruijin HospitalOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT07004647 | MT027 Cell Injection in Patients With Advanced Primary or Secondary Peritoneal Tumors | recruiting | N/A | 10 | Ruijin HospitalOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT06718244 | Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1 | recruiting | Phase 2 | 20 | Ruijin HospitalOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT06577532 | Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors | recruiting | Early Phase 1 | 56 | Ruijin HospitalOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT06972641 | Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation | recruiting | Phase 2 / Phase 3 | 126 | Ruijin HospitalOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT04072042 | BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced or Metastatic Sarcoma(BIOVAS) | recruiting | Phase 2 | 30 | Ruijin HospitalOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT06963632 | A Real-world Study on Golidocitinib-based Therapeutic Regimens for the Treatment of Patients With Peripheral T-cell Lymphoma(JOYCE) | not yet recruiting | — | 1,000 | Ruijin HospitalOTHER | 0 | May 9, 2025 | clinicaltrials |
| NCT04460248 | Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL) | active not recruiting | Phase 2 | 40 | Ruijin HospitalOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT06943690 | Safety and Efficacy Study of Single-port Robotic Versus Multi-port Robotic Radical Rectal Cancer Surgery | not yet recruiting | N/A | 212 | Ruijin HospitalOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT06935136 | Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell Lymphoma | not yet recruiting | N/A | 60 | Ruijin HospitalOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT06788600 | Mechanistic Study of EBV mRNA Vaccine (WGc-043) in EBV-Positive Relapsed/Refractory Lymphoma(WGc-043) | not yet recruiting | — | 15 | Ruijin HospitalOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT05916248 | Combination Therapy of Personalized mRNA-0217 Vaccines and Pembrolizumab in Patients With Advanced Solid Tumors | recruiting | Early Phase 1 | 34 | Ruijin HospitalOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT06901999 | Methotrexate or Thiotepa Combined With R-CHOP and Orelabrutinib in CNSL Patients | not yet recruiting | Phase 2 | 23 | Ruijin HospitalOTHER | 0 | Mar 30, 2025 | clinicaltrials |
| NCT06888037 | Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer | not yet recruiting | Phase 2 | 55 | Ruijin HospitalOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06567353 | A Multi-mode Thermophysical Immunotherapy Study for Breast Cancer Liver Metastases | recruiting | N/A | 10 | Ruijin HospitalOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT06876688 | Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma | recruiting | Phase 2 | 30 | Ruijin HospitalOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT06876701 | The Treatment of Newly Diagnosed CD19+Mixed Phenotype Acute Leukemia in Adults | not yet recruiting | Early Phase 1 | 10 | Ruijin HospitalOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT06863441 | The Value of PET Imaging Targeting Granzyme B in Predicting Efficacy and Prognosis in T-NK Cell Lymphoma | not yet recruiting | — | 50 | Ruijin HospitalOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06849921 | Precise Design of Cell Therapy for Relapsed and Refractory Hematological Tumors | active not recruiting | N/A | 200 | Ruijin HospitalOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT06779435 | A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL | recruiting | — | 400 | Ruijin HospitalOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06826885 | Safety and Efficacy of IMPT or IMRT for Breast Cancer(SEPPT-BC) | recruiting | — | 500 | Ruijin HospitalOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT06800768 | The Value of 68Ga-FAPI PET/CT in Detecting Recurrent and Metastatic Lesions in Patients with Thyroid Cancer After Surgery | recruiting | — | 40 | Ruijin HospitalOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06795113 | Optimization of 18F-FDG PET/CT Response Assessment and Prognostic Evaluation Strategies for High-Metabolism Lymphoma | recruiting | — | 4,000 | Ruijin HospitalOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT06695013 | Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHL(CART R/R NHL) | recruiting | Phase 2 | 144 | Ruijin HospitalOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT06765915 | Avapritinib Maintenance for AML With KIT Mutations | not yet recruiting | Phase 2 | 47 | Ruijin HospitalOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT06765928 | Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT | not yet recruiting | Phase 2 | 73 | Ruijin HospitalOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT06755775 | PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma | recruiting | — | 150 | Ruijin HospitalOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT06756217 | 68Ga-grazytracer PET/CT for Early Assessment of Response to Neoadjuvant Immunotherapy in Resectable NSCLC | recruiting | — | 40 | Ruijin HospitalOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT06701357 | CR-CHOP+X in Previously Untreated DEL | recruiting | Phase 2 | 49 | Ruijin HospitalOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06748521 | Dynamic CtDNA-guided Targeted Therapy in DLBCL | not yet recruiting | Phase 2 | 108 | Ruijin HospitalOTHER | 0 | Dec 27, 2024 | clinicaltrials |
| NCT06750991 | CD-RCHOP in ND DLBCL With a Combination of TP53 Mutation and Del(17p) | not yet recruiting | Phase 2 | 34 | Ruijin HospitalOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06746194 | The Value of 68Ga-FAPI PET/CT in the Efficacy Evaluation of Advanced Unresectable Hepatocellular Carcinoma Patients Undergoing Systemic Antitumor Therapy | recruiting | — | 40 | Ruijin HospitalOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT06747299 | The Value of Artificial Intelligence-based 18F-FDG PET/CT in Diferential Diagnosis, Efficacy Prediction and Prognosis Prediction of T-NK Cell Lymphoma: a Clinical Study | not yet recruiting | — | 200 | Ruijin HospitalOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT04926766 | Super Hypofractionated Irradiation for Whole Breast Treatment(SHIFT) | active not recruiting | N/A | 217 | Ruijin HospitalOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT06026488 | Real-World Study of DLBCL With Different Genetic Subtypes | recruiting | — | 10,000 | Ruijin HospitalOTHER | 1 | Dec 19, 2024 | clinicaltrials |
| NCT06644287 | The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Advanced Soft Tissue Sarcomas | recruiting | — | 40 | Ruijin HospitalOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT06730529 | The Value of 68Ga-FAPI PET/CT in Preoperative Evaluation of Thyroid Cancer with Lymph Node Metastases | recruiting | — | 40 | Ruijin HospitalOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06597539 | The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Advanced Hepatobiliary Malignancy | recruiting | — | 40 | Ruijin HospitalOTHER | 1 | Dec 11, 2024 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials